Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 GeneticVariation group BEFREE Mechanisms involving deregulated processing of proteins such as amyloid beta (Aβ) oligomerization; tau hyperphosphorylation, prion misfolding; α-synuclein accumulation/lewy body formation, chaperone deregulation, acetylcholine depletion, adenosine 2A (A2A) receptor hyperactivation, secretase deregulation, leucine-rich repeat kinase 2 (LRRK2) mutation and mitochondrial proteinopathies have deeper implications in neurodegenerative disorders. 31584139 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE α-synuclein is a predominantly expressing neuronal protein for understanding the neurodegenerative disorders. 31761041 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE The misfolding and aggregation of the largely disordered protein, α-synuclein, is a central pathogenic event that occurs in the synucleinopathies; a group of neurodegenerative disorders that includes Parkinson's disease. 31848207 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. 31293044 2020
Entrez Id: 23411
Gene Symbol: SIRT1
SIRT1
0.400 Biomarker group BEFREE This review examines experimental and clinical evidence relating to the potential role of SIRT1 and SIRT2, and their modulators in neurodegenerative diseases. 31812544 2020
Entrez Id: 2056
Gene Symbol: EPO
EPO
0.400 Biomarker group BEFREE Recombinant human erythropoietin (EPO) supplementation is one method of treating neurodegenerative disease by reducing the generation of ROS. 31813204 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE However, there is significant overlap and co-occurrence of α-synuclein and Tau pathologies in a spectrum of neurodegenerative diseases. 29738880 2020
Entrez Id: 4137
Gene Symbol: MAPT
MAPT
0.400 Biomarker group BEFREE Misfolding and aggregate formation by the tau protein has been closely related with neurotoxicity in a large group of human neurodegenerative disorders, which includes Alzheimer's disease. 31521630 2020
Entrez Id: 6310
Gene Symbol: ATXN1
ATXN1
0.400 GeneticVariation group BEFREE Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by abnormal expansion of glutamine (Q) encoding CAG repeats in the gene Ataxin-1 (ATXN1). 31696233 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE Synucleinopathies are neurodegenerative diseases characterized by the accumulation of either neuronal/axonal or glial insoluble proteinaceous aggregates mainly composed of α-synuclein (α-syn). 31693290 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE Parkinson's disease (PD) is a common neurodegenerative disorder characterized by loss of dopaminergic neurons in substantia nigra region and the presence of α-synuclein aggregates in the striatum and surrounding areas of brain. 31834548 2020
Entrez Id: 4137
Gene Symbol: MAPT
MAPT
0.400 Biomarker group BEFREE Tauopathies such as Alzheimer's disease (AD), Pick's disease (PiD), Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) etc. represent a group of age-related neurodegenerative disorders in which tau protein loses its normal conformation mostly due to hyperphosphorylation and subsequent formation of the aggregates of defined shapes, known as Neurofibrillary Tangles (NFTs). 31715291 2020
Entrez Id: 6310
Gene Symbol: ATXN1
ATXN1
0.400 AlteredExpression group BEFREE Understanding how Ataxin-1 expression is regulated in the human brain could inspire novel molecular therapies for this fatal, dominantly inherited neurodegenerative disease. 31381977 2020
Entrez Id: 4803
Gene Symbol: NGF
NGF
0.400 Biomarker group BEFREE She discovered the nerve growth factor, which is applied in various fields of neurology, concerning neurodegenerative diseases. 30700208 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE Cell-to-cell transmission of proteopathic alpha-synuclein (α-syn) seeds is increasingly thought to underlie the progression of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and related synucleinopathies. 30760864 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE Parkinson's disease (PD) is a serious neurodegenerative disease and is characterized by abnormal α-synuclein (α-syn) accumulation in Lewy bodies (LB) and Lewy neurites (LN), which makes α-syn an important imaging target for PD. 30277753 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE Parkinson's disease (PD) is one of the several neurodegenerative diseases where accumulation of aggregated proteins like α-synuclein occurs. 30218400 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 GeneticVariation group BEFREE These data indicate that although aggregation of PAP and SNCA causes severe neurodegenerative diseases, PAP -/- with absence of the Snca does not appear to interrupt the cerebellar architecture development and zone and stripe pattern formation. 31509576 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE Aggregation of the amyloid-forming α-synuclein (αS) protein is closely associated with the etiology of Parkinson's disease (PD), the most common motor neurodegenerative disorder. 31356747 2019
Entrez Id: 4137
Gene Symbol: MAPT
MAPT
0.400 Biomarker group BEFREE Tauopathies are a class of neurodegenerative diseases that are characterized by pathological aggregation of tau protein, which is accompanied by synaptic disorders. 30809933 2019
Entrez Id: 4803
Gene Symbol: NGF
NGF
0.400 Biomarker group BEFREE These studies demonstrate that microglia cells are a new target cell of NGF in the brain and have therapeutic significance: i) they establish that the neuroprotective actions of hNGFp relies on a widespread exposure of the brain, ii) they identify a new anti-neurodegenerative pathway, linking hNGFp to inflammatory chemokines and cytokines via microglia, a common target for new therapeutic opportunities for neurodegenerative diseases, iii) they extend the neuroprotective potential of hNGFp beyond its classical cholinergic target, thereby widening the range of neurological diseases for which this neurotrophic factor might be used therapeutically, iv) they help interpreting the results of current NGF clinical trials in AD and the design of future trials with this new potent therapeutic candidate. 30391352 2019
Entrez Id: 4137
Gene Symbol: MAPT
MAPT
0.400 Biomarker group BEFREE The accumulation of tau protein aggregates is a pathological hallmark in Alzheimer's disease (AD) and other neurodegenerative diseases. 30814358 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE The α-synuclein transmission hypothesis has profound implications for treatment of what is currently an intractable neurodegenerative disease. 31170426 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.400 Biomarker group BEFREE Several of these pyridine-fused rigid polyheterocycles are shown to bind to Aβ and α-synuclein fibrils, which are associated with neurodegenerative diseases. 30862161 2019
Entrez Id: 4137
Gene Symbol: MAPT
MAPT
0.400 Biomarker group BEFREE Four-repeat (4R-) tauopathies are a group of neurodegenerative diseases defined by cytoplasmic inclusions predominantly composed of tau protein isoforms with four microtubule-binding domains. 31238088 2019